Patents Examined by Lynn Bristol
-
Patent number: 11976136Abstract: The present invention provides fully IgG bi-specific antibodies comprising designed residues in the interface of the heavy chain-heavy chain (CH3/CH3) domains, processes for preparing said fully IgG bi-specific antibodies, and nucleic acids, vectors and host cells encoding the same.Type: GrantFiled: July 17, 2020Date of Patent: May 7, 2024Assignees: Eli Lilly and Company, The University of North Carolina at Chapel HillInventors: Hector Aldaz, Shane Krummen Atwell, Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
-
Patent number: 11970533Abstract: Antibodies binding to human claudin 18.2 (CLDN 18.2) and bispecific antibodies binding to both human CLDN 18.2 and PD-L1, pharmaceutical compositions comprising such, and methods of using such for treating target diseases including cancer.Type: GrantFiled: June 17, 2021Date of Patent: April 30, 2024Assignee: SPARX BIOSCIENCE LIMITEDInventors: Guidong Zhu, Jingdong Ye, Jichun Ma, Jingdong Qin, Hongyu Zhao
-
Patent number: 11965019Abstract: Provided herein are stabilized chimeric Fabs derived from a parent chimeric Fab having a lambda light chain. The stabilized chimeric Fabs comprise an immunoglobulin heavy chain polypeptide construct from the parent chimeric Fab, having a CH1 sequence and a VH sequence, as well as a Vlambda-Ckappa chimeric light chain construct. The Vlambda sequence of the chimeric light chain construct corresponds to that of the parent chimeric Fab, and comprises one or more stabilizing amino acid modifications that increase the thermal stability of the stabilized chimeric Fab compared to the parent chimeric Fab. The stabilized Fabs are useful as therapeutic polypeptides, or can be used to prepare antibody constructs in other formats. The stabilized chimeric Fabs may also be useful generally to increase the stability of antibodies having lambda light chains.Type: GrantFiled: June 29, 2018Date of Patent: April 23, 2024Assignee: ZYMEWORKS BC INC.Inventors: Dunja Urosev, Yang-Chieh Chou
-
Patent number: 11964998Abstract: The present invention relates to a method for purifying anti-IL-6 receptor antibodies from a sample comprising said antibodies and impurities, through the use of a three-chromatographic columns procedure, including a chromatography on Fluorapatite-containing resin. The invention is also concerned with pharmaceutical compositions comprising the purified antibodies obtainable by the process of the invention.Type: GrantFiled: August 30, 2018Date of Patent: April 23, 2024Assignee: FRESENIUS KABI DEUTSCHLAND GMBHInventors: Harry-James Sutter, Xavier Le Saout
-
Patent number: 11958913Abstract: The present invention relates to a mutant polypeptide linker for preparing multispecific antibodies, multispecific antibodies, and methods for producing multispecific antibodies.Type: GrantFiled: January 9, 2018Date of Patent: April 16, 2024Assignee: BIOMUNEX PHARMACEUTICALSInventors: Eugene Zhukovsky, Olivier Leger
-
Patent number: 11958902Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: July 27, 2020Date of Patent: April 16, 2024Assignee: Merck Sharp & Dohme LLCInventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
-
Patent number: 11959118Abstract: The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc region.Type: GrantFiled: October 20, 2020Date of Patent: April 16, 2024Assignee: Merck Sharp & Dohme LLCInventors: Terrance A. Stadheim, Dongxin Zha, Liming Liu
-
Patent number: 11952424Abstract: The invention relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein the base antibody portion is connected by a linker to the at least one additional binding domain, wherein each binding domain of the base antibody portion and each of the at least one additional binding domains all have a common variable region, and wherein the linker comprises a hinge sequence or a sequence derived from a hinge sequence. The invention also relates to a multivalent antibody which comprises: a base antibody portion which comprises two binding domains; and at least one additional binding domain, wherein at least one additional binding domain comprises a CH1 region and is connected to the base antibody portion by said linker, linking a variable region of the base antibody portion and the CH1 region, and wherein the multivalent antibody binds to at least three different epitopes.Type: GrantFiled: March 29, 2019Date of Patent: April 9, 2024Assignee: merus n.v.Inventors: Cornelis Adriaan de Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
-
Patent number: 11944648Abstract: A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR that can trigger T-cell activation upon detection of either CD19 or CD20 (or both). It is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.Type: GrantFiled: August 25, 2023Date of Patent: April 2, 2024Assignees: The Regents of the University of California, Seattle Children's HospitalInventors: Yvonne Y. Chen, Eugenia Zah, Michael C. Jensen
-
Patent number: 11944643Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: GrantFiled: March 30, 2018Date of Patent: April 2, 2024Assignee: CELLECTIS SAInventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
-
Patent number: 11945873Abstract: Antitumor antagonists that bind specifically to immune checkpoint regulators, angiogenesis pathway regulators and/or TGF pathway regulators are disclosed. Also disclosed are methods for treating proliferative disorders, infections, and immunological disorders with the antitumor antagonists described herein.Type: GrantFiled: April 16, 2021Date of Patent: April 2, 2024Assignee: GENSUN BIOPHARMA, INC.Inventors: Jackie Sheng, Bo Liu, Margaret Karow
-
Patent number: 11926667Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.Type: GrantFiled: October 12, 2021Date of Patent: March 12, 2024Assignee: Janssen Biotech, Inc.Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen
-
Patent number: 11919970Abstract: Provided are ROR1 binding molecules, including anti-ROR1 antibodies, including antibody fragments such as variable heavy chain (VH) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). In some embodiments, the antibodies specifically bind to ROR1. Among the antibodies are human antibodies, including those that compete for binding to ROR1 with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.Type: GrantFiled: December 14, 2020Date of Patent: March 5, 2024Assignee: Juno Therapeutics, Inc.Inventors: Yan Chen, Steven M. Shamah, Csaba Pazmany, Jui Dutta-Simmons
-
Patent number: 11912782Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: March 29, 2021Date of Patent: February 27, 2024Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Patent number: 11911348Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: October 9, 2020Date of Patent: February 27, 2024Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Patent number: 11912766Abstract: The invention provides methods and compositions for the treatment of cancer using anti-Siglec-7 antibodies that have reduced effector function.Type: GrantFiled: January 11, 2019Date of Patent: February 27, 2024Assignee: Allakos, Inc.Inventors: Christopher Bebbington, Wouter Korver, Nenad Tomasevic
-
Patent number: 11905331Abstract: The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.Type: GrantFiled: November 10, 2017Date of Patent: February 20, 2024Assignee: KUMHO HT, INC.Inventors: Gil Yong Ji, Kwon Pyo Hong, Eui Sup Lee, Yoo Ri Moon, Sangsoon Yoon
-
Patent number: 11891454Abstract: The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.Type: GrantFiled: July 17, 2020Date of Patent: February 6, 2024Assignee: Ichnos Sciences SAInventors: Stanislas Blein, Romain Ollier, Darko Skegro, Samuel Hou
-
Patent number: 11884720Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.Type: GrantFiled: August 1, 2016Date of Patent: January 30, 2024Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth Nahrwold, Doris Rau
-
Patent number: 11873339Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.Type: GrantFiled: June 22, 2020Date of Patent: January 16, 2024Assignee: PIERRE FABRE MEDICAMENTInventors: John Lippincott, Edward Thein Htun Van Der Horst, Sung Young Kim, Leonard G Presta, Jan-Willem Theunissen